Human Chorionic Gonadotropin (hCG), Qualitative, Urine
Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced by the fetal placenta during pregnancy. HCG maintains the corpus luteum during pregnancy, causing it to secrete progesterone, which is needed to develop a thick uterine lining of tissue and blood vessels. This lining sustains the growing fetus and helps it to thrive. hCG can be detected in the serum or urine as soon as 1 week after conception. Levels increase throughout the first trimester, and serum quantitative levels can determine the gestational age of the fetus. After approximately 12 weeks, serum hCG levels will begin to fall. Levels are approximately 50 – 100 mIU/mL after the first missed menstruation. Peak levels are reached 60 – 80 days after the last menstrual period (LMP) to approximately 30,000 – 100,000 mIU/mL, and levels then decrease to a level of 5,000 – 10,000 mIU/mL at about 90 days after LMP and stay the same until delivery.
Increased levels of hCG are seen in multiple pregnancy, ectopic pregnancy, molar pregnancy, choriocarcinoma, or recent terminated pregnancy. Decreased hCG values may indicate threatened abortion, missed abortion, or intrauterine death. Increased hCG values may also be seen in tumors of the ovaries, bladder, pancreas, stomach, lungs, or testicular cancer in males. There are many more specific tumor markers. Elevated hCG cannot diagnose a tumor and a low level does not exclude it, although measuring hCG during cancer treatment can indicate how well the cancer is responding to the treatment. hCG in conjunction with AFP, unconjugated estriol, and inhibin A is often included in a Quad Screen Profile, which can help rule out Down’s syndrome, Trisomy 18, and neural tubal defects.
- To confirm pregnancy and evaluate gestation
- As an aid to diagnose an ectopic pregnancy
- To help diagnose and monitor a pregnancy complication/rejection (spontaneous abortion), and monitoring a woman after a miscarriage
- In diagnosis and treatment monitoring of trophoblastic disease or germ cell tumors of the testes or ovary
- Prenatal screening for chromosomal abnormalities (first and/or second trimester maternal screen)
Increased in:
- Pregnancy
- Ectopic pregnancy
- Trophoblastic tumors such as hydatidiform mole and choriocarcinoma of uterus
- Also might be increased due to ectopic hCG production by other malignancies such as testis, stomach, pancreas, lung, colon, and liver
Decreased in:
- (rapid decrease):
- Pregnancy termination
- Pregnancy ejection
- Threatened abortion
Negative (Not Detected)
Immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Urine collected in a sterile container.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Clin Obstet Gynecol. 2003;46:523. [PMID: 12972735]
- CMAJ. 2005;173:905. [PMID: 16217116]
- Clin Biochem. 2004 Jul;37(7):549-61. [PMID: 15234236]
- Obstet Gynecol. 2009 Feb;113(2 Pt 2):518-9. [PMID: 19155941]
- Ann Endocrinol (Paris). 1984;45(4-5):269-80. [PMID: 6085538]
- Scand J Clin Lab Invest Suppl. 1993;216:97-104. [PMID: 7690985]
- Burtis C, Ashwood E, and Bruns D. Fundamentals of Clinical Chemistry. St. Louis: Saunders (2008).
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757